FDA Accepts GSK Filing for Expanded Use of RSV Shot in Younger Adults

• click to rate

  Posted by Two Blokes Jul 14 - Filed in Stock - 2 views
  
  FDA accepts GSK's filing to extend Arexvy's RSV vaccine use to high-risk adults under 50, with a decision due in 2026.